Roggwil, July 26, 2021 – In 2021, sales of the tinniwell are expected to at least double. In order to meet the high demand, the start of production of the 5th series was brought forward in July. This was originally planned for late autumn this year. The supply with the system is thus secured in the current target markets.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
T. +41 714500668